FR22C1058I1 - 2-FLUORO-N-METHYL-4-[7-(QUINOLINE-6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE-2-YL]BENZAMIDE TABLET FORMULATION - Google Patents

2-FLUORO-N-METHYL-4-[7-(QUINOLINE-6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE-2-YL]BENZAMIDE TABLET FORMULATION

Info

Publication number: FR22C1058I1
Authority: FR; France
Prior art keywords: imidazo; benzamide; ylmethyl; quinoline; triazine
Prior art date: 2014-07-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1058C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-25

Filing date

2022-12-06

Publication date

2023-01-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1058(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-12-06 Application filed by Novartis AG filed Critical Novartis AG

2023-01-06 Publication of FR22C1058I1 publication Critical patent/FR22C1058I1/en

2023-11-17 Application granted granted Critical

2023-11-17 Publication of FR22C1058I2 publication Critical patent/FR22C1058I2/en

Status Active legal-status Critical Current

Links

LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 title 1
239000007916 tablet composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

FR22C1058C 2014-07-25 2022-12-06 TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE Active FR22C1058I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462028865P	2014-07-25	2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en)	2014-07-25	2015-07-22	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (2)

Publication Number	Publication Date
FR22C1058I1 true FR22C1058I1 (en)	2023-01-06
FR22C1058I2 FR22C1058I2 (en)	2023-11-17

Family

ID=53762251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1058C Active FR22C1058I2 (en)	2014-07-25	2022-12-06	TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE

Country Status (29)

Country	Link
US (4)	US10085993B2 (en)
EP (2)	EP3848376A1 (en)
JP (3)	JP6770946B2 (en)
KR (2)	KR20230136693A (en)
CN (2)	CN106714784A (en)
AR (1)	AR101286A1 (en)
AU (4)	AU2015293539A1 (en)
CA (1)	CA2954840A1 (en)
CL (1)	CL2017000180A1 (en)
CO (1)	CO2017000586A2 (en)
DK (1)	DK3172209T3 (en)
EA (2)	EA039220B1 (en)
EC (1)	ECSP17011672A (en)
ES (1)	ES2857523T3 (en)
FR (1)	FR22C1058I2 (en)
GT (1)	GT201700007A (en)
HU (2)	HUE053346T2 (en)
IL (1)	IL250166B (en)
JO (1)	JO3618B1 (en)
MX (2)	MX2017001177A (en)
MY (1)	MY187276A (en)
PE (1)	PE20170523A1 (en)
PH (1)	PH12017500121A1 (en)
PL (1)	PL3172209T3 (en)
PT (1)	PT3172209T (en)
SG (2)	SG11201700147SA (en)
SI (1)	SI3172209T1 (en)
TW (2)	TWI724993B (en)
WO (1)	WO2016012963A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104245701A (en)	2012-04-03	2014-12-24	诺华有限公司	Combination products with tyrosine kinase inhibitors and their use
MY187276A (en) *	2014-07-25	2021-09-17	Novartis Ag	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN116172869A (en)	2016-08-10	2023-05-30	豪夫迈·罗氏有限公司	Pharmaceutical compositions comprising inhibitors of Akt protein kinase
WO2022007752A1 (en) *	2020-07-06	2022-01-13	苏州晶云药物科技股份有限公司	New crystal form of benzamide compound and dihydrochloride thereof, and preparation method therefor
CN118251220A (en) *	2022-01-19	2024-06-25	江苏奥赛康药业有限公司	Composition of tricyclic compound containing pyrimidine group, and preparation method and application thereof
WO2023249994A1 (en) *	2022-06-22	2023-12-28	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
WO2007014124A2 (en) *	2005-07-22	2007-02-01	Myriad Genetics, Inc.	High drug load formulations and dosage forms
WO2007031933A2 (en)	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) *	2006-10-12	2014-10-07	Pharmascience Inc.	Pharmaceutical compositions comprising intra- and extra- granular fractions
LT3034075T (en) *	2006-11-22	2018-11-26	Incyte Holdings Corporation	Imidazotriazines and imidazopyrimidines as kinase inhibitors
NZ589622A (en) *	2008-05-21	2012-10-26	Incyte Corp	Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
PL2498756T5 (en) *	2009-11-09	2023-04-17	Wyeth Llc	Tablet formulations of neratinib maleate
PL2574168T3 (en) *	2010-05-21	2016-10-31		Topical formulation for a jak inhibitor
US20120009259A1 (en) *	2010-07-06	2012-01-12	Urbain Alfons Clementina Delaet	Formulation for co-therapy treatment of diabetes
KR102245985B1 (en)	2012-08-16	2021-04-30	노파르티스 아게	Combination of pi3k inhibitor and c-met inhibitor
MY187276A (en) *	2014-07-25	2021-09-17	Novartis Ag	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

2015
- 2015-07-22 MY MYPI2017700061A patent/MY187276A/en unknown
- 2015-07-22 EP EP20210458.4A patent/EP3848376A1/en active Pending
- 2015-07-22 WO PCT/IB2015/055561 patent/WO2016012963A1/en active Application Filing
- 2015-07-22 CA CA2954840A patent/CA2954840A1/en active Pending
- 2015-07-22 EP EP15744702.0A patent/EP3172209B1/en active Active
- 2015-07-22 PT PT157447020T patent/PT3172209T/en unknown
- 2015-07-22 HU HUE15744702A patent/HUE053346T2/en unknown
- 2015-07-22 KR KR1020237031767A patent/KR20230136693A/en not_active Application Discontinuation
- 2015-07-22 SG SG11201700147SA patent/SG11201700147SA/en unknown
- 2015-07-22 JP JP2017504062A patent/JP6770946B2/en active Active
- 2015-07-22 US US15/328,661 patent/US10085993B2/en active Active
- 2015-07-22 SG SG10201900648SA patent/SG10201900648SA/en unknown
- 2015-07-22 AU AU2015293539A patent/AU2015293539A1/en not_active Abandoned
- 2015-07-22 PL PL15744702T patent/PL3172209T3/en unknown
- 2015-07-22 PE PE2017000097A patent/PE20170523A1/en unknown
- 2015-07-22 EA EA201790259A patent/EA039220B1/en unknown
- 2015-07-22 SI SI201531507T patent/SI3172209T1/en unknown
- 2015-07-22 ES ES15744702T patent/ES2857523T3/en active Active
- 2015-07-22 EA EA202191301A patent/EA202191301A1/en unknown
- 2015-07-22 CN CN201580052264.4A patent/CN106714784A/en active Pending
- 2015-07-22 KR KR1020177004939A patent/KR102581121B1/en active IP Right Grant
- 2015-07-22 DK DK15744702.0T patent/DK3172209T3/en active
- 2015-07-22 MX MX2017001177A patent/MX2017001177A/en unknown
- 2015-07-22 CN CN202210949714.1A patent/CN115364061A/en active Pending
- 2015-07-23 TW TW104123937A patent/TWI724993B/en active
- 2015-07-23 JO JOP/2015/0174A patent/JO3618B1/en active
- 2015-07-23 AR ARP150102336A patent/AR101286A1/en unknown
- 2015-07-23 TW TW110109338A patent/TW202200148A/en unknown
2017
- 2017-01-17 IL IL250166A patent/IL250166B/en active IP Right Grant
- 2017-01-20 PH PH12017500121A patent/PH12017500121A1/en unknown
- 2017-01-24 CL CL2017000180A patent/CL2017000180A1/en unknown
- 2017-01-24 CO CONC2017/0000586A patent/CO2017000586A2/en unknown
- 2017-01-25 MX MX2021000595A patent/MX2021000595A/en unknown
- 2017-01-25 GT GT201700007A patent/GT201700007A/en unknown
- 2017-02-24 EC ECIEPI201711672A patent/ECSP17011672A/en unknown
2018
- 2018-07-23 AU AU2018207947A patent/AU2018207947A1/en not_active Abandoned
- 2018-09-18 US US16/134,162 patent/US10596178B2/en active Active
2020
- 2020-02-07 AU AU2020200912A patent/AU2020200912B2/en active Active
- 2020-02-13 US US16/789,655 patent/US20210113569A1/en not_active Abandoned
- 2020-03-27 JP JP2020058164A patent/JP7002587B2/en active Active
2021
- 2021-04-23 AU AU2021202500A patent/AU2021202500A1/en not_active Abandoned
- 2021-12-15 US US17/644,473 patent/US20220249498A1/en active Pending
- 2021-12-24 JP JP2021211526A patent/JP2022046659A/en active Pending
2022
- 2022-12-06 FR FR22C1058C patent/FR22C1058I2/en active Active
- 2022-12-19 HU HUS2200054C patent/HUS2200054I1/en unknown

Also Published As

Publication number	Publication date
AU2021202500A1 (en)	2021-05-20
BR112017000953A2 (en)	2017-11-14
CL2017000180A1 (en)	2017-09-15
HUS2200054I1 (en)	2023-01-28
PL3172209T3 (en)	2021-06-14
FR22C1058I2 (en)	2023-11-17
NZ728089A (en)	2024-01-26
CA2954840A1 (en)	2016-01-28
EA039220B1 (en)	2021-12-20
AU2020200912B2 (en)	2021-01-28
CN106714784A (en)	2017-05-24
GT201700007A (en)	2018-12-18
PT3172209T (en)	2021-02-11
ECSP17011672A (en)	2018-03-31
AU2020200912A1 (en)	2020-02-27
IL250166B (en)	2021-01-31
SI3172209T1 (en)	2021-03-31
US10085993B2 (en)	2018-10-02
US20210113569A1 (en)	2021-04-22
AU2015293539A1 (en)	2017-02-02
ES2857523T3 (en)	2021-09-29
TWI724993B (en)	2021-04-21
IL250166A0 (en)	2017-03-30
JO3618B1 (en)	2020-08-27
SG10201900648SA (en)	2019-02-27
MX2017001177A (en)	2017-05-01
EP3172209A1 (en)	2017-05-31
EA201790259A1 (en)	2017-06-30
KR102581121B1 (en)	2023-09-21
SG11201700147SA (en)	2017-02-27
CO2017000586A2 (en)	2017-06-20
CN115364061A (en)	2022-11-22
AU2018207947A1 (en)	2018-08-09
TW202200148A (en)	2022-01-01
JP7002587B2 (en)	2022-01-20
EA202191301A1 (en)	2021-11-30
DK3172209T3 (en)	2021-02-22
PH12017500121A1 (en)	2017-05-29
US20170231997A1 (en)	2017-08-17
US20190015418A1 (en)	2019-01-17
AR101286A1 (en)	2016-12-07
JP6770946B2 (en)	2020-10-21
KR20170039211A (en)	2017-04-10
US20220249498A1 (en)	2022-08-11
MY187276A (en)	2021-09-17
HUE053346T2 (en)	2021-06-28
EP3172209B1 (en)	2020-12-02
EP3848376A1 (en)	2021-07-14
JP2017521469A (en)	2017-08-03
JP2020114852A (en)	2020-07-30
PE20170523A1 (en)	2017-05-17
JP2022046659A (en)	2022-03-23
TW201613595A (en)	2016-04-16
US10596178B2 (en)	2020-03-24
WO2016012963A1 (en)	2016-01-28
MX2021000595A (en)	2021-04-13
KR20230136693A (en)	2023-09-26

Publication	Publication Date	Title
HK1256195A1 (en)	2019-09-13	Stable anti-ifnar1 formulation
GB2551985B (en)	2019-01-30	Novel formulation
DK3355884T3 (en)	2021-08-02	TETRAHYDRO-1H-PYRIDO [3,4-B] INDOL ANTIOSTROGEN MEDICINES
FR22C1058I1 (en)	2023-01-06	2-FLUORO-N-METHYL-4-[7-(QUINOLINE-6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE-2-YL]BENZAMIDE TABLET FORMULATION
IL254476A0 (en)	2017-11-30	Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor
PL3359543T3 (en)	2019-10-31	Cucurbituril derivatives
SI3114126T1 (en)	2019-01-31	1,2-dihydro-3h-pyrrolo(1,2-c)imidazol-3-one derivatives and their use as antibacterial agents
PT3426294T (en)	2023-06-06	Pharmaceutical formulation
HK1245653A1 (en)	2018-08-31	Pharmaceutical formulation
IL266537A (en)	2019-07-31	Pharmaceutical formulation
IL253177A0 (en)	2017-08-31	Pharmaceutical formulation
ZA201807851B (en)	2022-04-28	Pharmaceutical formulation
GB201608356D0 (en)	2016-06-29	Formulation
EP3383371C0 (en)	2024-05-01	Pharmaceutical formulation
GB201506755D0 (en)	2015-06-03	Novel pharmaceutical formulation
GB201511246D0 (en)	2015-08-12	Pharmaceutical formulation
GB201707615D0 (en)	2017-06-28	Formulation
EP3227292A4 (en)	2018-06-13	4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
HK1244277A1 (en)	2018-08-03	New substituted triazolopyrimidines as anti-malarial agents
PL3559185T3 (en)	2022-12-19	Clear-rinse formulation
GB201604545D0 (en)	2016-05-04	Novel pharmaceutical formulation
GB201609925D0 (en)	2016-07-20	Formulation
GB201602048D0 (en)	2016-03-23	Formulation
TH1601001194A (en)	2017-10-19	New triazolo[4,5-d]pyrimidine derivatives
AU2014904868A0 (en)	2014-12-18	4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS